Collaboration and License Agreements - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		12 Months Ended
	Oct. 31, 2023	Feb. 28, 2023	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Commitments and Contingencies
Collaboration revenue					$ 210,782	$ 129,013
Vertex
Commitments and Contingencies
Vertex agreement, term		4 years
Milestone payment	$ 17,500		$ 75,000	$ 17,500	75,000
Shares issued		$ 19,400
Cumulative catch-up adjustment				$ 7,800	38,700
Collaboration revenue					209,800	129,000
Vertex | Private Placement
Commitments and Contingencies
Net proceeds from issuance of common stock		$ 26,300
Number of shares purchases in equity investment (in shares)		1,618,613
Consideration amount		$ 485,000
Vertex | License
Commitments and Contingencies
Up-front payment		223,700
Revenue, remaining performance obligation, amount		232,000			20,200
Premium		$ 6,900
Vertex | Cost reimbursements
Commitments and Contingencies
Collaboration revenue					15,800	17,500
Vertex | Recognition of upfront and milestone payments
Commitments and Contingencies
Collaboration revenue					70,500	7,800
Vertex | Deferred revenue at inception
Commitments and Contingencies
Collaboration revenue					123,500	$ 103,700
Pierrepont Therapeutics, Inc
Commitments and Contingencies
Revenue recognized					$ 1,000